Analiz Rodriguez
Concepts (281)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 14 | 2023 | 284 | 5.020 |
Why?
| Glioblastoma | 9 | 2023 | 99 | 3.150 |
Why?
| Neurosurgery | 7 | 2023 | 34 | 1.820 |
Why?
| Central Nervous System Neoplasms | 2 | 2023 | 57 | 1.660 |
Why?
| Hematologic Neoplasms | 2 | 2023 | 99 | 1.630 |
Why?
| T-Lymphocytes | 6 | 2023 | 373 | 1.510 |
Why?
| Glioma | 3 | 2020 | 78 | 1.370 |
Why?
| Biocompatible Materials | 5 | 2010 | 65 | 1.150 |
Why?
| Internship and Residency | 5 | 2023 | 501 | 1.130 |
Why?
| Organoids | 3 | 2022 | 41 | 1.060 |
Why?
| Immunotherapy, Adoptive | 4 | 2023 | 134 | 1.030 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 1 | 2023 | 22 | 0.920 |
Why?
| STAT2 Transcription Factor | 1 | 2021 | 7 | 0.840 |
Why?
| STAT1 Transcription Factor | 1 | 2021 | 27 | 0.830 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.830 |
Why?
| Humans | 48 | 2024 | 54284 | 0.830 |
Why?
| Biological Specimen Banks | 1 | 2021 | 21 | 0.810 |
Why?
| Physicians, Women | 3 | 2018 | 24 | 0.800 |
Why?
| Neurosurgical Procedures | 5 | 2023 | 120 | 0.800 |
Why?
| Foreign-Body Reaction | 3 | 2009 | 6 | 0.790 |
Why?
| Financing, Government | 1 | 2020 | 25 | 0.770 |
Why?
| Hyperthermia, Induced | 2 | 2019 | 107 | 0.770 |
Why?
| Implants, Experimental | 3 | 2009 | 6 | 0.770 |
Why?
| Drug Discovery | 1 | 2021 | 90 | 0.770 |
Why?
| Melanoma | 2 | 2023 | 313 | 0.770 |
Why?
| National Institutes of Health (U.S.) | 1 | 2020 | 49 | 0.760 |
Why?
| Neoplasms | 4 | 2023 | 1316 | 0.750 |
Why?
| DNA Modification Methylases | 1 | 2020 | 32 | 0.750 |
Why?
| Isocitrate Dehydrogenase | 1 | 2020 | 21 | 0.750 |
Why?
| DNA Repair Enzymes | 1 | 2020 | 50 | 0.740 |
Why?
| Sequence Analysis, RNA | 1 | 2020 | 107 | 0.710 |
Why?
| Societies, Medical | 1 | 2020 | 194 | 0.700 |
Why?
| Phototherapy | 1 | 2019 | 53 | 0.700 |
Why?
| Paranasal Sinus Neoplasms | 1 | 2019 | 27 | 0.700 |
Why?
| Tumor Suppressor Proteins | 1 | 2020 | 141 | 0.700 |
Why?
| Insurance, Health | 1 | 2020 | 132 | 0.700 |
Why?
| Cell Culture Techniques | 1 | 2019 | 112 | 0.690 |
Why?
| Insurance Coverage | 1 | 2020 | 107 | 0.690 |
Why?
| Nanostructures | 1 | 2019 | 53 | 0.680 |
Why?
| General Surgery | 1 | 2020 | 113 | 0.680 |
Why?
| Tumor Microenvironment | 5 | 2023 | 209 | 0.660 |
Why?
| Carcinoma | 1 | 2019 | 153 | 0.630 |
Why?
| Receptors, Antigen | 1 | 2017 | 2 | 0.620 |
Why?
| Biomedical Research | 1 | 2020 | 240 | 0.610 |
Why?
| Laser Therapy | 2 | 2016 | 91 | 0.580 |
Why?
| Recombinant Fusion Proteins | 1 | 2017 | 206 | 0.580 |
Why?
| Cell Line, Tumor | 6 | 2024 | 1550 | 0.540 |
Why?
| Syringomyelia | 1 | 2015 | 12 | 0.530 |
Why?
| Sexism | 1 | 2015 | 10 | 0.520 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 644 | 0.510 |
Why?
| Specialties, Surgical | 1 | 2015 | 38 | 0.500 |
Why?
| Skin Neoplasms | 1 | 2020 | 532 | 0.500 |
Why?
| Neuronavigation | 1 | 2014 | 11 | 0.490 |
Why?
| Bone Screws | 1 | 2014 | 36 | 0.480 |
Why?
| Leadership | 1 | 2015 | 114 | 0.480 |
Why?
| Child | 6 | 2023 | 7341 | 0.480 |
Why?
| Faculty, Medical | 1 | 2015 | 100 | 0.480 |
Why?
| Surgery, Computer-Assisted | 1 | 2014 | 53 | 0.470 |
Why?
| Lumbar Vertebrae | 1 | 2014 | 105 | 0.450 |
Why?
| Teaching | 1 | 2014 | 127 | 0.440 |
Why?
| Tomography, X-Ray Computed | 2 | 2019 | 1213 | 0.440 |
Why?
| Education, Medical, Graduate | 1 | 2015 | 225 | 0.440 |
Why?
| Female | 21 | 2023 | 28441 | 0.430 |
Why?
| Patient Care Team | 1 | 2014 | 273 | 0.420 |
Why?
| Materials Testing | 3 | 2009 | 62 | 0.420 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 164 | 0.410 |
Why?
| Disease Progression | 3 | 2020 | 913 | 0.400 |
Why?
| Trigeminal Neuralgia | 2 | 2021 | 7 | 0.390 |
Why?
| Spheroids, Cellular | 2 | 2021 | 26 | 0.390 |
Why?
| Giant Cells, Foreign-Body | 2 | 2009 | 2 | 0.380 |
Why?
| United States | 8 | 2023 | 5217 | 0.370 |
Why?
| Lymphocyte Activation | 1 | 2010 | 197 | 0.340 |
Why?
| Male | 15 | 2023 | 27334 | 0.340 |
Why?
| Transcriptome | 2 | 2021 | 346 | 0.330 |
Why?
| Stroke | 1 | 2014 | 526 | 0.330 |
Why?
| Multiple Myeloma | 1 | 2023 | 3035 | 0.330 |
Why?
| Career Choice | 3 | 2023 | 116 | 0.320 |
Why?
| T-Lymphocyte Subsets | 1 | 2008 | 41 | 0.320 |
Why?
| Cytokines | 3 | 2019 | 676 | 0.320 |
Why?
| Spinal Fusion | 2 | 2022 | 71 | 0.310 |
Why?
| Aphids | 1 | 2007 | 2 | 0.310 |
Why?
| Pheromones | 1 | 2007 | 2 | 0.310 |
Why?
| Solanum tuberosum | 1 | 2007 | 11 | 0.310 |
Why?
| Lung Neoplasms | 2 | 2024 | 642 | 0.310 |
Why?
| Antineoplastic Agents | 3 | 2023 | 1300 | 0.300 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2008 | 116 | 0.300 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 866 | 0.300 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2008 | 180 | 0.290 |
Why?
| Retrospective Studies | 8 | 2022 | 6432 | 0.280 |
Why?
| Stereotaxic Techniques | 2 | 2016 | 36 | 0.280 |
Why?
| Adult | 9 | 2022 | 14207 | 0.280 |
Why?
| Imaging, Three-Dimensional | 2 | 2016 | 171 | 0.250 |
Why?
| Macrophages | 3 | 2021 | 405 | 0.240 |
Why?
| Young Adult | 4 | 2022 | 4318 | 0.240 |
Why?
| History, 20th Century | 2 | 2021 | 114 | 0.240 |
Why?
| Combined Modality Therapy | 2 | 2016 | 692 | 0.240 |
Why?
| Disease Management | 2 | 2015 | 184 | 0.230 |
Why?
| Mass Behavior | 1 | 2023 | 1 | 0.230 |
Why?
| Oncolytic Viruses | 1 | 2023 | 12 | 0.230 |
Why?
| Oncolytic Virotherapy | 1 | 2023 | 18 | 0.230 |
Why?
| Middle Aged | 7 | 2022 | 13088 | 0.230 |
Why?
| Lymphoma | 1 | 2024 | 72 | 0.230 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 106 | 0.220 |
Why?
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2022 | 4 | 0.220 |
Why?
| Platybasia | 1 | 2022 | 6 | 0.220 |
Why?
| Zebrafish | 1 | 2023 | 57 | 0.220 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2023 | 278 | 0.220 |
Why?
| Antigens, Neoplasm | 1 | 2023 | 170 | 0.210 |
Why?
| Janus Kinase 1 | 1 | 2021 | 20 | 0.210 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2022 | 44 | 0.210 |
Why?
| Janus Kinase 2 | 1 | 2021 | 31 | 0.210 |
Why?
| Retinal Dehydrogenase | 1 | 2021 | 10 | 0.210 |
Why?
| Animals | 11 | 2024 | 14385 | 0.210 |
Why?
| Aged | 7 | 2023 | 10054 | 0.200 |
Why?
| Tissue Culture Techniques | 1 | 2021 | 46 | 0.200 |
Why?
| Microvascular Decompression Surgery | 1 | 2021 | 2 | 0.200 |
Why?
| Germ-Line Mutation | 1 | 2021 | 68 | 0.200 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2021 | 64 | 0.200 |
Why?
| Nitriles | 1 | 2021 | 69 | 0.200 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2021 | 93 | 0.200 |
Why?
| Cerebral Veins | 1 | 2021 | 16 | 0.200 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2021 | 142 | 0.200 |
Why?
| Biopsy | 2 | 2021 | 692 | 0.200 |
Why?
| Pyrazoles | 1 | 2021 | 110 | 0.190 |
Why?
| Cell Adhesion | 3 | 2010 | 171 | 0.190 |
Why?
| Congresses as Topic | 1 | 2020 | 52 | 0.190 |
Why?
| Cavernous Sinus | 1 | 2020 | 15 | 0.190 |
Why?
| Alcohol Oxidoreductases | 1 | 2020 | 14 | 0.190 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 295 | 0.190 |
Why?
| Databases as Topic | 1 | 2020 | 46 | 0.190 |
Why?
| Inpatients | 1 | 2022 | 204 | 0.190 |
Why?
| Medically Uninsured | 1 | 2020 | 51 | 0.190 |
Why?
| Pyrimidines | 1 | 2021 | 196 | 0.190 |
Why?
| Skull Base Neoplasms | 1 | 2020 | 23 | 0.180 |
Why?
| Methylation | 1 | 2020 | 130 | 0.180 |
Why?
| Decompression, Surgical | 2 | 2022 | 52 | 0.180 |
Why?
| Infrared Rays | 1 | 2019 | 27 | 0.180 |
Why?
| Meningioma | 1 | 2020 | 43 | 0.180 |
Why?
| Meningeal Carcinomatosis | 1 | 2019 | 6 | 0.180 |
Why?
| Propensity Score | 1 | 2020 | 137 | 0.180 |
Why?
| Proteomics | 1 | 2022 | 343 | 0.180 |
Why?
| Meningeal Neoplasms | 1 | 2020 | 50 | 0.180 |
Why?
| Silicone Elastomers | 2 | 2009 | 8 | 0.180 |
Why?
| Neuralgia | 1 | 2020 | 58 | 0.180 |
Why?
| Polyethylene Terephthalates | 2 | 2009 | 11 | 0.180 |
Why?
| Thiotepa | 1 | 2019 | 5 | 0.170 |
Why?
| Cognition | 2 | 2019 | 348 | 0.170 |
Why?
| Lasers | 1 | 2019 | 141 | 0.170 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2019 | 74 | 0.170 |
Why?
| Neoplasm Metastasis | 1 | 2019 | 252 | 0.170 |
Why?
| Socioeconomic Factors | 1 | 2021 | 642 | 0.160 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 206 | 0.160 |
Why?
| Magnetic Resonance Imaging | 2 | 2015 | 1604 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2021 | 271 | 0.150 |
Why?
| Pilot Projects | 1 | 2020 | 808 | 0.150 |
Why?
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 18 | 0.150 |
Why?
| Adolescent | 2 | 2021 | 6897 | 0.150 |
Why?
| Cell Proliferation | 3 | 2023 | 1096 | 0.150 |
Why?
| Health Services Accessibility | 1 | 2021 | 432 | 0.150 |
Why?
| Head and Neck Neoplasms | 1 | 2020 | 335 | 0.140 |
Why?
| Neoplasm Staging | 1 | 2019 | 806 | 0.140 |
Why?
| Transverse Sinuses | 1 | 2016 | 5 | 0.140 |
Why?
| Central Nervous System Vascular Malformations | 1 | 2016 | 13 | 0.140 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2019 | 552 | 0.140 |
Why?
| Intracranial Hypertension | 1 | 2016 | 31 | 0.140 |
Why?
| Immunohistochemistry | 1 | 2019 | 1089 | 0.140 |
Why?
| Rats, Sprague-Dawley | 3 | 2009 | 1663 | 0.140 |
Why?
| Oxygen | 1 | 2019 | 361 | 0.140 |
Why?
| Urinary Bladder, Neurogenic | 1 | 2015 | 8 | 0.140 |
Why?
| Muscular Dystrophies | 1 | 2015 | 16 | 0.130 |
Why?
| Sensation Disorders | 1 | 2015 | 14 | 0.130 |
Why?
| Watchful Waiting | 1 | 2015 | 29 | 0.130 |
Why?
| Unnecessary Procedures | 1 | 2015 | 25 | 0.130 |
Why?
| Asymptomatic Diseases | 1 | 2015 | 43 | 0.130 |
Why?
| Intestinal Diseases | 1 | 2015 | 36 | 0.130 |
Why?
| Cranial Irradiation | 1 | 2015 | 24 | 0.130 |
Why?
| Drug Implants | 1 | 2015 | 35 | 0.130 |
Why?
| Scoliosis | 1 | 2015 | 58 | 0.130 |
Why?
| Gait Disorders, Neurologic | 1 | 2015 | 36 | 0.130 |
Why?
| Immunotherapy | 1 | 2016 | 263 | 0.120 |
Why?
| Radiography | 1 | 2015 | 524 | 0.120 |
Why?
| Emergency Medicine | 1 | 2014 | 60 | 0.120 |
Why?
| Neurology | 1 | 2014 | 46 | 0.120 |
Why?
| Radiosurgery | 1 | 2015 | 122 | 0.120 |
Why?
| Rats | 3 | 2009 | 3415 | 0.110 |
Why?
| Comorbidity | 1 | 2015 | 663 | 0.110 |
Why?
| Mice | 4 | 2024 | 6413 | 0.110 |
Why?
| Behavior, Animal | 2 | 2019 | 200 | 0.110 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2023 | 219 | 0.110 |
Why?
| Aged, 80 and over | 2 | 2023 | 3431 | 0.100 |
Why?
| Treatment Outcome | 2 | 2020 | 5604 | 0.100 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 12 | 0.090 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 12 | 0.090 |
Why?
| Lectins, C-Type | 1 | 2010 | 32 | 0.090 |
Why?
| Interleukin-2 | 1 | 2010 | 75 | 0.090 |
Why?
| Surface Properties | 1 | 2010 | 79 | 0.090 |
Why?
| Interleukin-13 | 1 | 2009 | 16 | 0.090 |
Why?
| Follow-Up Studies | 1 | 2015 | 2387 | 0.090 |
Why?
| Cell Count | 1 | 2010 | 181 | 0.090 |
Why?
| Interleukin-4 | 1 | 2009 | 48 | 0.090 |
Why?
| Polyurethanes | 1 | 2009 | 9 | 0.090 |
Why?
| Interferon-gamma | 1 | 2010 | 195 | 0.080 |
Why?
| Maze Learning | 2 | 2019 | 55 | 0.080 |
Why?
| Chemokines | 1 | 2009 | 96 | 0.080 |
Why?
| Mice, Nude | 1 | 2009 | 283 | 0.080 |
Why?
| Cell Membrane | 1 | 2010 | 278 | 0.080 |
Why?
| Granulocytes | 1 | 2008 | 26 | 0.080 |
Why?
| Mice, Inbred BALB C | 1 | 2009 | 368 | 0.080 |
Why?
| Antigens, CD | 1 | 2010 | 242 | 0.080 |
Why?
| Immunity, Cellular | 1 | 2008 | 80 | 0.080 |
Why?
| Hexanols | 1 | 2007 | 1 | 0.080 |
Why?
| Terpenes | 1 | 2007 | 16 | 0.080 |
Why?
| Plant Diseases | 1 | 2007 | 13 | 0.080 |
Why?
| Polytetrafluoroethylene | 1 | 2007 | 36 | 0.080 |
Why?
| Infant, Newborn | 1 | 2015 | 2907 | 0.080 |
Why?
| Surgical Mesh | 1 | 2007 | 18 | 0.080 |
Why?
| Time Factors | 2 | 2019 | 3213 | 0.070 |
Why?
| Aldehydes | 1 | 2007 | 97 | 0.070 |
Why?
| Virus Diseases | 1 | 2007 | 44 | 0.070 |
Why?
| Flow Cytometry | 1 | 2010 | 546 | 0.070 |
Why?
| Infant | 1 | 2015 | 3817 | 0.070 |
Why?
| Child, Preschool | 1 | 2015 | 4147 | 0.070 |
Why?
| Apoptosis | 2 | 2023 | 1300 | 0.070 |
Why?
| Cells, Cultured | 1 | 2010 | 1737 | 0.070 |
Why?
| Prosencephalon | 1 | 2023 | 13 | 0.060 |
Why?
| Mesencephalon | 1 | 2023 | 16 | 0.060 |
Why?
| Chick Embryo | 1 | 2023 | 79 | 0.060 |
Why?
| Tamoxifen | 1 | 2023 | 60 | 0.060 |
Why?
| Cerebral Ventricles | 1 | 2023 | 25 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2019 | 1999 | 0.060 |
Why?
| Monensin | 1 | 2022 | 14 | 0.050 |
Why?
| Intracranial Pressure | 1 | 2022 | 32 | 0.050 |
Why?
| Steroids | 1 | 2022 | 53 | 0.050 |
Why?
| Nose | 1 | 2022 | 42 | 0.050 |
Why?
| Minority Groups | 1 | 2023 | 136 | 0.050 |
Why?
| Medicare | 1 | 2023 | 241 | 0.050 |
Why?
| Anniversaries and Special Events | 1 | 2021 | 15 | 0.050 |
Why?
| Trigeminal Nerve | 1 | 2021 | 9 | 0.050 |
Why?
| Monitoring, Physiologic | 1 | 2022 | 136 | 0.050 |
Why?
| Tretinoin | 1 | 2021 | 56 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 240 | 0.050 |
Why?
| Communication | 1 | 2023 | 273 | 0.050 |
Why?
| Decompression | 1 | 2020 | 2 | 0.050 |
Why?
| Tumor Cells, Cultured | 1 | 2021 | 477 | 0.050 |
Why?
| Trauma Centers | 1 | 2022 | 218 | 0.050 |
Why?
| Cell Movement | 1 | 2021 | 271 | 0.050 |
Why?
| Glucocorticoids | 1 | 2022 | 234 | 0.050 |
Why?
| Dexamethasone | 1 | 2022 | 435 | 0.050 |
Why?
| Cell Line | 1 | 2022 | 1153 | 0.040 |
Why?
| Injections, Intraperitoneal | 1 | 2019 | 59 | 0.040 |
Why?
| Receptors, AMPA | 1 | 2019 | 17 | 0.040 |
Why?
| Dentate Gyrus | 1 | 2019 | 17 | 0.040 |
Why?
| Dendritic Spines | 1 | 2019 | 21 | 0.040 |
Why?
| Protein Subunits | 1 | 2019 | 85 | 0.040 |
Why?
| Registries | 1 | 2021 | 553 | 0.040 |
Why?
| Synapses | 1 | 2019 | 90 | 0.040 |
Why?
| Movement | 1 | 2019 | 111 | 0.040 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 121 | 0.040 |
Why?
| Certification | 1 | 2018 | 47 | 0.040 |
Why?
| Faculty | 1 | 2018 | 84 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2023 | 1693 | 0.040 |
Why?
| Tissue Engineering | 2 | 2007 | 61 | 0.040 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1056 | 0.040 |
Why?
| Cadaver | 1 | 2016 | 113 | 0.030 |
Why?
| Personnel Selection | 1 | 2015 | 28 | 0.030 |
Why?
| RNA, Messenger | 1 | 2019 | 1202 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 684 | 0.030 |
Why?
| Mutation | 1 | 2021 | 1501 | 0.030 |
Why?
| Salvage Therapy | 1 | 2014 | 145 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2014 | 485 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2014 | 431 | 0.030 |
Why?
| Sex Factors | 1 | 2015 | 767 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 514 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2014 | 643 | 0.030 |
Why?
| Brain | 1 | 2019 | 1387 | 0.020 |
Why?
| Regenerative Medicine | 1 | 2007 | 9 | 0.020 |
Why?
| Tissue Adhesions | 1 | 2007 | 7 | 0.020 |
Why?
| Cell Communication | 1 | 2007 | 72 | 0.020 |
Why?
| Herniorrhaphy | 1 | 2007 | 26 | 0.020 |
Why?
| Fibrosis | 1 | 2007 | 208 | 0.020 |
Why?
| Cell Differentiation | 1 | 2007 | 720 | 0.020 |
Why?
|
|
Rodriguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|